NeuroOne Medical Technologies Corp (NMTC) FinancialsNMTCNeuroOne Medical Technologies Corp

Evaluating the bottom line, NeuroOne Medical Technologies Corp maintains a gross margin of 59.94%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -122.87%, while the net margin is -101.68%. These profitability ratios, combined with a Return on Equity (ROE) of -124.66%, provide a clear picture of how effectively NMTC converts its operational activities into shareholder value.

In the context of the broader market, NMTC competes directly with industry leaders such as CLGN and BMRA. With a market capitalization of $7.74M, it holds a significant position in the sector. When comparing efficiency, NMTC's gross margin of 59.94% stands against CLGN's -422.22% and BMRA's 8.14%. Such benchmarking helps identify whether NeuroOne Medical Technologies Corp is trading at a premium or discount relative to its financial performance.

Neuroone reported a gross margin of 59.94% in Q3 2026, showing improvement, but continues to face net income losses, with -$2,006,331 in Q3 2026. Year-to-date, the stock has plummeted by 83.38%, indicating severe financial distress.